Hans-Peter Gerber

Company: Sutro Biopharma

Job title: Chief Scientific Officer

Bio:

Hans-Peter brings 30 years of R&D experience in oncology drug development, specializing in antibody-drug conjugates (ADCs), redirected T-cell targeting compounds (bispecifics), and adoptive T-cell therapies (TCR-T and CAR-T cells). He has built successful drug development teams across pharma, biotech, and startups, overseeing preclinical development with low clinical attrition rates. Notably, he has contributed to the development of 6 of the 15 approved ADCs.

Seminars:

Novel & Dual Payloads: Assessing Linker Conjugation Technologies That Encourage Flexibility in Payloads 4:00 pm

Evaluating the right ratios, the advantages of releasing drugs in specific ratios, and which combination of drugs make sense when considering dual payloads Discussing how novel payloads hold promise to overcome drug resistance Advancing cytoxic or immune-stimulating payloads with novel MoAsRead more

day: Day One P3